Who
Adrienne L. Graves
Director
Company insider
Files Form 4 as: Director, Harrow; Director, Ocular Therapeutix; Director, Opus Genetics; Director, IVERIC bio; Director, Akorn; Director, TearLab.
In numbers
- Trades disclosed
- 80
- Buys
- 1
- Sells
- 1
- Bought
- $62K
- Sold
- $393K
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 3 Aug 2006
- Last trade
- 18 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 22 Jun 2026 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,248 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,248 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 18 May 2026filed 19 May 2026 | HROW HarrowPharmaceuticals | SEC FORM 4 Bought | $31K1,000 at $31.07 | filing |
| 18 May 2026filed 19 May 2026 | HROW HarrowPharmaceuticals | SEC FORM 4 Bought | $31K1,000 at $31.07 | filing |
| 20 Apr 2026filed 22 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —24,367 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —24,367 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —23,643 | filing |
| 1 Jan 2026filed 5 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —23,643 | filing |
| 20 Jun 2025filed 24 Jun 2025 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,339 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —79,592 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —79,504 at $0.00 | filing |
| 22 Oct 2024filed 24 Oct 2024 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —172,874 at $0.00 | filing |
| 24 Jul 2024filed 26 Jul 2024 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 24 Jul 2024filed 26 Jul 2024 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
News
Comparing Harrow (NASDAQ:HROW) & Teva Pharmaceutical Industries (NYSE:TEVA)HROW · tickerreport.com · 16 Oct 2026
0 headlines in the last 90 days name Adrienne L. Graves; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.